Myelodysplastic Syndromes Treatment

Introduction

If you or a family member has recently been told that the diagnosis is a myelodysplastic syndrome — usually shortened to MDS — you are probably trying to make sense of a lot of new information at once. MDS is not a single disease but a group of related bone marrow disorders. Some people live with it quietly for years with only mild changes in their blood counts. Others need active treatment soon after diagnosis. A smaller group go on to develop acute leukaemia.

This guide is written for adults who already have an MDS diagnosis (or are being investigated for one) and for family members helping them through it. It explains what MDS is, how doctors decide how serious it is, what the main treatment options look like, what to expect during and after treatment, and how life with MDS is typically managed over the long term. It does not replace your haematologist’s advice — MDS care is highly individual — but it should help you understand the language, the choices, and the road ahead.

What Are Myelodysplastic Syndromes?

The bone marrow is the soft tissue inside your larger bones. It is the factory that makes blood cells: red blood cells (which carry oxygen), white blood cells (which fight infection), and platelets (which help blood clot). In a healthy person, immature blood-forming cells called stem cells mature step by step into these three cell types and are then released into the bloodstream.

In myelodysplastic syndromes, the stem cells in the bone marrow carry genetic changes that make this maturing process go wrong. The marrow may look busy under the microscope, but many of the cells it makes are abnormal in shape or function (this is called dysplasia) and they often die before they leave the marrow. The result is the opposite of what you might expect: a crowded marrow but low numbers of working blood cells in the bloodstream — what doctors call cytopenias.

Three features define MDS:

• One or more low blood counts (low haemoglobin, low white cells, or low platelets)
• Abnormal-looking blood-forming cells in the marrow
• An increased risk — in some subtypes more than others — of progressing to acute myeloid leukaemia (AML)

A common question is whether MDS is cancer. Most current classifications, including the World Health Organization (WHO) classification of myeloid neoplasms, group MDS within the broader family of myeloid neoplasms — that is, blood cancers that begin in the bone marrow. So yes, MDS is generally regarded as a form of blood cancer, although it often behaves more slowly and differently from acute leukaemia. Many people with lower-risk MDS live with stable disease for years.

Types of Myelodysplastic Syndromes

MDS is not one disease. The WHO and the International Consensus Classification (ICC) divide MDS into several subtypes based on what the bone marrow and blood look like under the microscope and on specific genetic changes. You do not need to memorise the categories, but it helps to recognise the kinds of terms your reports may use.

Subtypes defined by genetic changes

Some subtypes are defined by a specific chromosome or gene change. The best-known example is MDS with isolated del(5q), in which a portion of one chromosome 5 is missing. This subtype tends to respond well to certain treatments. Other subtypes are defined by mutations in genes such as SF3B1 or by the presence of TP53 mutations, which tend to behave more aggressively.

Subtypes defined by appearance and blast count

Other categories are described by how many cell lines are affected and by the percentage of immature cells (called blasts) in the marrow. As the blast count rises, the disease behaves more like leukaemia. Once blasts reach 20% of marrow cells, the disease is classified as AML rather than MDS.

Therapy-related MDS

MDS that develops after previous chemotherapy or radiation therapy (for an earlier cancer, for example) is called therapy-related MDS. It often has different genetic features and tends to be more difficult to treat than MDS that arises on its own.

Risk groups: how doctors classify severity

Beyond the WHO subtype, haematologists use a risk score to estimate how an individual person’s MDS is likely to behave. The most widely used systems are the Revised International Prognostic Scoring System (IPSS-R) and the newer Molecular IPSS (IPSS-M), which adds gene mutation information. These scores combine:

• The percentage of blasts in the bone marrow
• The pattern of low blood counts
• Chromosome changes (cytogenetics)
• Specific gene mutations (in IPSS-M)

The result places a person into a risk group ranging from very low to very high. In broad terms, doctors think of MDS as lower-risk or higher-risk. This distinction shapes the entire treatment plan: lower-risk MDS is usually managed to improve blood counts and quality of life, while higher-risk MDS is treated more intensively to control the disease and reduce the chance of progression to AML.

Causes and Risk Factors

In most people with MDS, no single cause can be pinpointed. The genetic damage in the bone marrow stem cells builds up gradually, often over many years, and most diagnoses occur after age 60. Several factors are associated with a higher risk.

Age. MDS becomes more common with age. The median age at diagnosis is in the seventies.

Previous cancer treatment. Chemotherapy — particularly alkylating agents and topoisomerase II inhibitors — and radiation therapy can damage bone marrow stem cells and lead to therapy-related MDS years later.

Environmental and occupational exposures. Long-term exposure to benzene (found in some industrial settings, petroleum products, and tobacco smoke) is a recognised risk factor. Some pesticides and heavy metals have also been linked.

Smoking. Tobacco smoke contains benzene and other marrow-toxic chemicals.

Inherited conditions. A small number of people inherit gene changes that predispose to MDS or other bone marrow failure syndromes — for example, Fanconi anaemia, dyskeratosis congenita, or germline mutations in genes such as DDX41, RUNX1, or GATA2. These are far more relevant when MDS appears in younger adults or children, or when there is a family history of blood disorders.

MDS is not contagious. It is not caused by diet, stress, or anything you did or did not do.

Signs and Symptoms

If you are reading this after diagnosis, you have likely already noticed some of the symptoms below or have had blood tests showing low counts. Many people with MDS, especially in the early stages, have no symptoms at all and are picked up incidentally when a routine blood test shows persistently low haemoglobin or platelets.

When symptoms do appear, they usually reflect the type of cell that is low:

• Low red cells (anaemia) — tiredness, breathlessness on exertion, pale skin, dizziness, reduced exercise tolerance, palpitations
• Low white cells (neutropenia) — frequent or unusually severe infections, mouth ulcers, fevers
• Low platelets (thrombocytopenia) — easy bruising, bleeding gums, nosebleeds, tiny red spots on the skin (petechiae)

Once you are in active care, the symptoms to watch for are slightly different. New or worsening tiredness, unexplained fever, unusual bleeding, or sudden bruising are reasons to contact your haematology team promptly — they may signal a drop in counts, an infection, or disease progression that needs assessment.

How MDS Is Diagnosed

If you are reading this guide, you have probably already been through most of these tests. They are summarised here so you can understand what each one tells your doctors.

Blood tests

A complete blood count (CBC) measures haemoglobin, white cells, and platelets. A peripheral blood smear looks at the shape and appearance of the cells under a microscope. Other tests rule out conditions that can mimic MDS, including vitamin B12 and folate deficiency, iron studies, thyroid function, kidney and liver tests, HIV, and tests for autoimmune causes of low counts.

Bone marrow aspirate and biopsy

Cytogenetics and molecular testing

The marrow sample is also sent for cytogenetic analysis (looking at chromosomes) and molecular testing (looking at specific gene mutations). These results are essential. They confirm the diagnosis in borderline cases, identify subtypes such as MDS with del(5q), and feed directly into the risk score (IPSS-R or IPSS-M) that will guide treatment.

Other investigations

Depending on age, fitness, and the treatment being considered, you may also have tests of heart, lung, kidney, and liver function, viral screens (hepatitis B and C, HIV, CMV), and HLA tissue typing if stem cell transplantation is a possibility. HLA typing of siblings may also be arranged.

Treatment of MDS

MDS treatment is highly individualised. The right plan depends on the risk group, the specific subtype, your symptoms, your age and general fitness, other medical conditions, and what matters to you. The major international frameworks — including the NCCN Guidelines and the European LeukemiaNet (ELN) recommendations — broadly separate the approach by risk group.

The watch-and-wait approach

For some people with very low-risk MDS who have only mildly low blood counts and no symptoms, immediate treatment may not be necessary. The plan is regular monitoring of blood counts, with treatment started if symptoms develop or counts fall further. This is not the same as “doing nothing”: it is a structured strategy based on the fact that starting therapy too early can carry its own risks without clear benefit.

Supportive care

Supportive care aims to relieve symptoms caused by low blood counts and to prevent complications. It is part of the care plan for almost everyone with MDS, alongside whatever disease-directed therapy is being used.

Red cell transfusions are given for symptomatic anaemia. Many people with lower-risk MDS depend on transfusions every few weeks. Over time, repeated transfusions can lead to iron overload, which can damage the heart and liver. Iron chelation therapy — oral or injected medication that helps the body remove excess iron — is considered when iron stores rise significantly, particularly in people who are likely to keep receiving transfusions for a long time.

Platelet transfusions may be needed for active bleeding or when platelet counts are very low. Routine prophylactic platelets are used selectively.

Growth factors are medications that stimulate the marrow to make more of a particular cell type:

• Erythropoiesis-stimulating agents (ESAs) such as erythropoietin or darbepoetin can raise haemoglobin and reduce transfusion needs in some people with lower-risk MDS, particularly those with relatively low baseline erythropoietin levels.
• Luspatercept, a newer drug that helps red cell maturation, is used in some patients with lower-risk MDS, especially those with ring sideroblasts or SF3B1 mutations, who remain transfusion-dependent despite or without ESA therapy.
• G-CSF may be used short-term to boost white cell counts during infections, although it is not used routinely to prevent infections in all MDS patients.

Infection prevention includes hand hygiene, avoiding contact with people who are unwell, staying up to date with recommended vaccinations as advised by your team, and seeking medical attention quickly for any fever.

Disease-modifying drug therapy

Several medications act on the underlying disease rather than only on its symptoms.

Hypomethylating agents (HMAs) — azacitidine and decitabine — are the backbone of treatment for higher-risk MDS in people who are not undergoing immediate transplant, and they are also used in some lower-risk situations. They are given in cycles, typically over several days each month, by injection under the skin or by infusion. Responses usually take three to six cycles to appear, and treatment is generally continued for as long as it is helping. An oral combination of decitabine with cedazuridine is available in some settings.

Lenalidomide is an oral medication particularly effective in MDS with isolated del(5q). It can reduce transfusion needs and, in some people, restore normal blood counts for extended periods.

Immunosuppressive therapy — for example, antithymocyte globulin (ATG) with ciclosporin — is occasionally used in a small group of younger patients whose MDS has features overlapping with aplastic anaemia.

Targeted therapies for MDS continue to evolve. Drugs aimed at specific mutations, and combinations of HMAs with venetoclax (already standard in AML), are being studied actively in MDS. Whether any of these is appropriate is a decision made by your haematology team based on your subtype and the current evidence.

Chemotherapy

Major societies generally consider transplant for people with higher-risk MDS who are medically fit and have a suitable donor. It is sometimes also considered in lower-risk MDS that is no longer responding to other treatments or has high-risk genetic features. Age alone is not an absolute barrier; biological fitness and other medical conditions matter more than the number on the calendar. Reduced-intensity conditioning transplants have widened the option to older and less fit patients.

The transplant process has several stages:

1. Pre-transplant evaluation — detailed assessment of fitness, infections, organ function, and dental health; discussions about fertility preservation where relevant.
2. Donor selection — a matched sibling, a matched unrelated donor from a registry, or a half-matched (haploidentical) family donor.
3. Conditioning — high-dose chemotherapy, sometimes with radiation, given over several days to suppress the immune system and reduce diseased marrow.
4. Stem cell infusion — the donor cells are given through a vein, similar to a transfusion.
5. Engraftment — over two to four weeks, the donor cells settle into the marrow and start making new blood cells. This is the period of highest infection risk and usually requires hospital admission.
6. Recovery and long-term follow-up — immune recovery takes months to years, with medications to prevent and treat graft-versus-host disease (GVHD), regular monitoring, and gradual return to normal activities.

Transplant offers the chance of long-term remission or cure but carries significant risks, including infection, GVHD, organ toxicity, and transplant-related mortality. Whether transplant is the right path is one of the most important conversations to have with a specialist transplant team.

Lifestyle and Self-Management

MDS treatment is delivered by your medical team, but day-to-day choices also affect how you feel and how safely you can navigate treatment.

Infection prevention. Low white cells and treatment-related immune suppression raise the risk of infection. Wash hands often, avoid close contact with people who are obviously unwell, take care with food hygiene (well-cooked foods, washed fruits, avoidance of unpasteurised products), and ask your team which vaccinations are appropriate and when. Discuss any planned dental work, travel, or close contact with young children who have recently been vaccinated.

Bleeding precautions. If your platelets are low, your team will advise on activities to avoid (contact sports, heavy lifting) and on medications that affect bleeding (aspirin, ibuprofen, certain herbal supplements). Use a soft toothbrush; avoid flossing roughly.

Activity. Gentle, regular activity is generally encouraged as tolerated. Fatigue is one of the most common and underestimated symptoms of MDS, and movement — even modest walking — often helps more than complete rest.

Diet. A balanced diet is recommended; specific iron, B12, or folate supplements are only useful if a deficiency has been documented. People receiving chemotherapy or transplant may be given more specific food-safety guidance (sometimes called a “neutropenic diet”) by their team.

Smoking and alcohol. Stopping smoking is strongly advised; smoking damages the marrow further and worsens cardiovascular risk during treatment. Alcohol should be limited and discussed with your doctor, as it can worsen low platelets and interact with medications.

Mental health. Living with a serious blood disorder is emotionally demanding. Anxiety, low mood, and uncertainty about the future are common. Psychological support, counselling, peer-support groups, and conversations with your team about how you are coping are all part of good MDS care.

Monitoring and Follow-up

MDS requires regular follow-up, both during active treatment and during periods of stable disease.

Typical monitoring includes:

• Regular blood counts — weekly or more often during active treatment, less frequently when stable
• Iron studies in people who are transfusion-dependent, to guide chelation therapy
• Bone marrow examinations repeated when there is a change in counts, before major treatment decisions, or to assess response to therapy — not routinely on a fixed schedule
• Heart, liver, and kidney function checks, particularly if treatment or iron overload could affect these organs
• Infection surveillance, including viral monitoring after transplant

The aim is to detect changes early — whether that means a falling count that needs transfusion, a response to treatment, or a sign of progression that calls for a change in plan.

Complications

The main complications of MDS arise either from the low blood counts themselves, from the treatments, or from disease progression.

From treatment: side effects of HMAs (low counts, nausea, fatigue, injection-site reactions), of lenalidomide (low counts, blood clots, rashes), of intensive chemotherapy (mouth sores, hair loss, infection, organ effects), and of transplant (GVHD, infections, infertility, late effects on organs and on the risk of other cancers).

Progression to acute myeloid leukaemia (AML). This is one of the most important risks of MDS. The chance of progression varies enormously between subtypes — very low in some lower-risk forms, substantially higher in higher-risk MDS. Regular monitoring is designed to catch progression early so that treatment can be adjusted.

Living with MDS

For many people, MDS becomes a long-term condition managed over years. The shape of life with MDS depends on the risk group and the response to treatment.

People with lower-risk MDS often have periods of relatively stable health punctuated by clinic visits, blood tests, and transfusions. Fatigue is often the most disabling symptom and may require pacing of activities, planning around transfusion days, and frank conversations with employers and family about what is realistic.

People with higher-risk MDS may go through more intensive phases — cycles of HMA therapy, hospital stays, or transplant — followed by recovery and follow-up. After successful transplant, life gradually returns to fuller activity, though the recovery is measured in months and the surveillance is lifelong.

Practical things that help include:

• Keeping a personal record of blood counts, transfusions, and medications
• Knowing whom to call out of hours and what symptoms warrant urgent contact
• Carrying a card or letter that identifies you as having MDS and lists your key medications, especially if you travel
• Having a trusted person who can come to important consultations and help process information
• Asking questions — even ones that feel basic. MDS is complicated even for doctors who do not see it every day.

MDS in Children

MDS is far less common in children than in adults, and childhood MDS behaves differently in important ways. It is usually managed at specialist paediatric haematology centres.

In children, MDS is more often linked to inherited bone marrow failure syndromes (such as Fanconi anaemia, Shwachman-Diamond syndrome, or germline mutations in genes such as GATA2 or SAMD9/SAMD9L). For this reason, genetic testing and assessment of other organ systems is a routine part of paediatric MDS evaluation, and family members may also need testing.

The treatment landscape is also different. Hypomethylating agents and lenalidomide, which are central to adult MDS care, play a smaller role in children. Allogeneic stem cell transplant is generally the treatment of choice for most children with MDS who have a suitable donor, with the type of conditioning chosen carefully according to the child’s underlying condition. Children with inherited bone marrow failure syndromes typically need reduced-intensity conditioning because their tissues are more sensitive to chemotherapy and radiation.

Long-term follow-up is especially important in children, both because of the underlying genetic conditions and because of the late effects of transplant on growth, fertility, and other organ systems.

When to Seek Urgent Medical Attention

If you are living with MDS, certain symptoms should prompt urgent contact with your haematology team or attendance at an emergency department:

• A temperature of 38°C (100.4°F) or higher, or chills and shaking, particularly if your white cells are known to be low
• Unusual or heavy bleeding — nosebleeds that will not stop, blood in urine or stool, vomiting blood, or new widespread bruising
• Sudden severe headache, vision changes, weakness or numbness on one side, or confusion (possible signs of bleeding into the brain)
• Chest pain, severe breathlessness at rest, or fainting
• New rapid weight loss, drenching night sweats, or rapidly enlarging lymph nodes

It is reasonable to err on the side of calling. In MDS, infections and bleeding can become serious quickly, and your team would rather assess you early.

Frequently Asked Questions

Is MDS a type of cancer?

Most current classifications, including the WHO classification, place MDS within the family of myeloid neoplasms — cancers that begin in the bone marrow. It often behaves more slowly than acute leukaemia, but it is generally considered a form of blood cancer.

Will my MDS turn into leukaemia?

Some people with MDS go on to develop acute myeloid leukaemia, but many do not. The risk depends heavily on the subtype, the genetic features, and the risk score (IPSS-R or IPSS-M). Your haematologist can give you a much more individual sense of risk based on your own results.

Is bone marrow transplant the only way to cure MDS?

At present, allogeneic stem cell transplant is the only treatment generally regarded as potentially curative. Other treatments can control the disease, reduce transfusion needs, and improve quality of life, sometimes for many years, but they are not usually considered curative.

Am I too old for treatment?

Age alone is rarely a reason not to treat MDS. Many older adults benefit greatly from supportive care, growth factors, and hypomethylating agents. Even transplant is now performed in carefully selected people in their sixties and seventies, using lower-intensity conditioning. What matters most is overall fitness and other medical conditions.

Can MDS be inherited?

Most adult MDS is not inherited. A small proportion of cases — more common in younger patients or where there is a family history of blood disorders or unexplained cytopenias — involves inherited gene changes. If your doctors suspect an inherited cause, they may suggest genetic counselling and testing for you and possibly for relatives, particularly if a family member is being considered as a stem cell donor.

Why do I still feel exhausted even when my haemoglobin is “not too bad”?

Fatigue in MDS is not only about haemoglobin. The disease itself, inflammation, poor sleep, emotional strain, other medications, and side effects of treatment all contribute. Tell your team if fatigue is affecting daily life; there are usually things that can help.

Are clinical trials worth considering?

MDS is an area of active research, and clinical trials are how newer treatments become available. Whether a trial is suitable depends on your subtype, prior treatments, and overall situation. Your haematologist can tell you what is currently open and whether any might be relevant.

Can I travel with MDS?

Many people with stable MDS travel, including by air. Practical considerations include timing trips around transfusions, carrying a summary of your medical history and medications, ensuring access to medical care at your destination, and discussing any infection risks (such as live vaccines for travel) with your team in advance.

Conclusion

Myelodysplastic syndromes are a complex group of bone marrow disorders, but they are also conditions for which understanding the type, the risk group, and the available treatments makes a real difference. For some people, MDS is managed for years with supportive care and growth factors. For others, hypomethylating agents, lenalidomide, or allogeneic stem cell transplant become part of the journey. The right path is rarely obvious from the outside and is built through careful conversation between you, your family, and a haematology team familiar with the disease.

Whatever your risk group, the same broad principles apply: get a clear diagnosis with full genetic information, understand where you sit on the risk scale, ask what each treatment is meant to achieve, and stay connected to a team that can adjust the plan as things change. MDS is a long road for many, but it is one that is increasingly well charted.